Ian Krop

Ian Krop is Associate Director for Clinical Research at Yale Cancer Center and a leading expert in HER2-targeted therapy and antibody-drug conjugates for breast cancer. He spent the majority of his career at Dana-Farber Cancer Institute before joining Yale, and throughout that time he has been one of the most productive and influential clinical investigators in HER2+ breast cancer. Krop was a principal investigator on several of the pivotal trials establishing trastuzumab emtansine (T-DM1) as a standard of care in HER2+ metastatic breast cancer, including the EMILIA and TH3RESA trials, and he has continued this work with trastuzumab deruxtecan (T-DXd). Krop has also made significant contributions to the treatment of HER2+ breast cancer with brain metastases, a particularly challenging clinical scenario. He led the TBCRC 022 trial evaluating lapatinib and capecitabine in HER2+ brain metastases, and he has been involved in multiple subsequent studies evaluating neratinib, tucatinib, and T-DXd in patients with active or stable brain metastases. This work has helped improve outcomes for a historically underserved patient population. Beyond clinical trials, Krop has conducted translational research into mechanisms of resistance to HER2-directed therapy and has studied predictive biomarkers for ADC response. He is a nationally recognized educator and mentor, and his move to Yale reflects his continued commitment to building world-class breast cancer clinical trials infrastructure.